Evidence map›Paper›PMID 32878881›Full record

ArticleBiology open2020

Vishvanath Tiwari

Open access · goldAbstract read
In one paragraph

Article in Biology open, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.3field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Vishvanath TiwariDepartment of Biochemistry, Central University of Rajasthan, Bandarsindri, Ajmer 305817, India vishvanath@curaj.ac.in.ORCID 0000-0003-1664-3871
Central University of Rajasthan · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

SARS-like coronavirus (SARS-CoV2) has emerged as a global threat to humankind and is rapidly spreading. The infectivity, pathogenesis and infection of this virus are dependent on the interaction of SARS-CoV2 spike protein with human angiotensin converting enzyme 2 (hACE2). Spike protein contains a receptor-binding domain (RBD) that recognizes hACE-2. In the present study, we are reporting a

Indexed as

Combinatorial Chemistry TechniquesAngiotensin-Converting Enzyme 2Antiviral AgentsBetacoronavirusCell DeathHumansMolecular Docking SimulationPeptidyl-Dipeptidase AProtein BindingProtein DomainsSARS-CoV-2Spike Glycoprotein, CoronavirusThermodynamicsACE2 protein, humanAngiotensin-Converting Enzyme 2Antiviral AgentsPeptidyl-Dipeptidase ASpike Glycoprotein, CoronavirusAngiotensin converting enzyme 2De novo designingHybrid antiviral moleculeMolecular dynamics simulationRetrosynthetic analysisSARS-CoV2 spike glycoprotein

Identifiers

PMID32878881
PMCPMC7595696
OpenAlexW3082111906

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.